Latest news and press releases about Climb Bio, Inc. (CLYM): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy.
Price
| Price | $14.11 |
| Market Cap | $808M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.49 |
| EV / EBITDA | -14.25 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -31.79% |
| Return on Invested Capital | -26.89% |
| Return on Assets | -23.40% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABOS · ACTU · AGEN · ANIX · ENTX · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of CLYM: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks